Business of Biosimilars Event

The biosimilars debate is intensifying with Ted Kennedy’s new proposed legislation for 13.5 years of data exclusivity for biologics – almost double the time period proposed by the Obama administration. With the cost of US biologics already topping $60 billion and rapidly growing, there is increased pressure to approve a regulatory pathway for biosimilars.

Are you prepared to compete in this complex and controversial environment? The Business of Biosimilars Event will help answer your key questions and address the risks and rewards of entering into this dynamic market.

*Understand current legislation & regulatory developments

*Evaluate exclusivity periods and their impact on competition

*Prepare to overcome regulatory challenges with insights and updates from a former FDA representative

*Examine the current regulatory pathway in Europe with case examples of approved biosimilars and developments from the EGA

To view the full agenda click here!

Start the conversations now:

Join the LinkedIn Group!

Follow us on Twitter!

Share this article with your social network, just click below to share now!

Share |